S&P 500   5,069.53 (-0.38%)
DOW   39,069.23 (-0.16%)
QQQ   436.55 (-0.05%)
AAPL   181.16 (-0.75%)
MSFT   407.54 (-0.68%)
META   481.74 (-0.47%)
GOOGL   137.57 (-4.44%)
AMZN   174.73 (-0.15%)
TSLA   199.40 (+3.87%)
NVDA   790.92 (+0.35%)
NIO   5.65 (+4.63%)
AMD   176.01 (-0.29%)
BABA   76.51 (+0.72%)
T   16.59 (-1.25%)
F   11.95 (-1.57%)
MU   89.46 (+4.02%)
CGC   3.47 (+3.27%)
GE   154.77 (+0.94%)
DIS   107.69 (-0.05%)
AMC   4.45 (+0.23%)
PFE   27.18 (-2.09%)
PYPL   59.33 (+0.29%)
XOM   104.25 (+0.39%)
S&P 500   5,069.53 (-0.38%)
DOW   39,069.23 (-0.16%)
QQQ   436.55 (-0.05%)
AAPL   181.16 (-0.75%)
MSFT   407.54 (-0.68%)
META   481.74 (-0.47%)
GOOGL   137.57 (-4.44%)
AMZN   174.73 (-0.15%)
TSLA   199.40 (+3.87%)
NVDA   790.92 (+0.35%)
NIO   5.65 (+4.63%)
AMD   176.01 (-0.29%)
BABA   76.51 (+0.72%)
T   16.59 (-1.25%)
F   11.95 (-1.57%)
MU   89.46 (+4.02%)
CGC   3.47 (+3.27%)
GE   154.77 (+0.94%)
DIS   107.69 (-0.05%)
AMC   4.45 (+0.23%)
PFE   27.18 (-2.09%)
PYPL   59.33 (+0.29%)
XOM   104.25 (+0.39%)
S&P 500   5,069.53 (-0.38%)
DOW   39,069.23 (-0.16%)
QQQ   436.55 (-0.05%)
AAPL   181.16 (-0.75%)
MSFT   407.54 (-0.68%)
META   481.74 (-0.47%)
GOOGL   137.57 (-4.44%)
AMZN   174.73 (-0.15%)
TSLA   199.40 (+3.87%)
NVDA   790.92 (+0.35%)
NIO   5.65 (+4.63%)
AMD   176.01 (-0.29%)
BABA   76.51 (+0.72%)
T   16.59 (-1.25%)
F   11.95 (-1.57%)
MU   89.46 (+4.02%)
CGC   3.47 (+3.27%)
GE   154.77 (+0.94%)
DIS   107.69 (-0.05%)
AMC   4.45 (+0.23%)
PFE   27.18 (-2.09%)
PYPL   59.33 (+0.29%)
XOM   104.25 (+0.39%)
S&P 500   5,069.53 (-0.38%)
DOW   39,069.23 (-0.16%)
QQQ   436.55 (-0.05%)
AAPL   181.16 (-0.75%)
MSFT   407.54 (-0.68%)
META   481.74 (-0.47%)
GOOGL   137.57 (-4.44%)
AMZN   174.73 (-0.15%)
TSLA   199.40 (+3.87%)
NVDA   790.92 (+0.35%)
NIO   5.65 (+4.63%)
AMD   176.01 (-0.29%)
BABA   76.51 (+0.72%)
T   16.59 (-1.25%)
F   11.95 (-1.57%)
MU   89.46 (+4.02%)
CGC   3.47 (+3.27%)
GE   154.77 (+0.94%)
DIS   107.69 (-0.05%)
AMC   4.45 (+0.23%)
PFE   27.18 (-2.09%)
PYPL   59.33 (+0.29%)
XOM   104.25 (+0.39%)
NASDAQ:RAPT

RAPT Therapeutics (RAPT) Stock Price, News & Analysis

$9.42
+0.70 (+8.03%)
(As of 02/26/2024 ET)
Today's Range
$8.50
$9.62
50-Day Range
$6.87
$26.45
52-Week Range
$6.86
$31.45
Volume
1.80 million shs
Average Volume
1.30 million shs
Market Capitalization
$324.05 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$28.67

RAPT Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.57 Rating Score
Upside/​Downside
204.3% Upside
$28.67 Price Target
Short Interest
Bearish
11.48% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.87
Upright™ Environmental Score
News Sentiment
-0.49mentions of RAPT Therapeutics in the last 14 days
Based on 48 Articles This Week
Insider Trading
Selling Shares
$95,236 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($3.11) to ($3.32) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.97 out of 5 stars

Medical Sector

186th out of 942 stocks

Pharmaceutical Preparations Industry

79th out of 425 stocks


RAPT stock logo

About RAPT Therapeutics Stock (NASDAQ:RAPT)

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. The company's lead oncology drug candidate is FLX475, an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. It also focuses on the development of hematopoietic progenitor kinase 1 inhibitor. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

RAPT Stock Price History

RAPT Stock News Headlines

RAPT May 2024 17.500 put
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
UBS Group Downgrades RAPT Therapeutics (NASDAQ:RAPT) to Neutral
UBS Downgrades RAPT Therapeutics (RAPT)
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Rapt Therapeutics just downgraded at Leerink, here's why
What's Going On With RAPT Therapeutics Stock On Wednesday?
Rapt Therapeutics just downgraded at JPMorgan, here's why
Rapt Therapeutics just downgraded at Cantor Fitzgerald, here's why
See More Headlines
Receive RAPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for RAPT Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/11/2023
Today
2/26/2024
Next Earnings (Estimated)
3/12/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:RAPT
Fax
N/A
Employees
129
Year Founded
2015

Price Target and Rating

Average Stock Price Target
$28.67
High Stock Price Target
$48.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+214.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.57
Research Coverage
14 Analysts

Profitability

Net Income
$-83,840,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.53 million
Book Value
$8.20 per share

Miscellaneous

Free Float
32,504,000
Market Cap
$313.73 million
Optionable
Optionable
Beta
0.66

Social Links

(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Brian Russell Wong M.D. (Age 52)
    Ph.D., CEO, President & Director
    Comp: $797.5k
  • Mr. Rodney K. B. Young (Age 61)
    CFO, Principal Accounting Officer & Secretary
    Comp: $585k
  • Dr. William HoDr. William Ho (Age 58)
    Chief Medical Officer
    Comp: $590k
  • Steve Young Ph.D.
    Vice President of Technology
  • Dr. Dirk G. Brockstedt Ph.D. (Age 55)
    Chief Scientific Officer
    Comp: $490.25k
  • Mr. Michael Listgarten
    General Counsel
  • Ms. Gwen R. Carscadden (Age 63)
    Chief Human Resources Officer
  • Dr. Paul Kassner (Age 57)
    Senior Vice President of Quantitative & Computational Biology
  • Dr. David Wustrow (Age 65)
    Senior Vice President of Drug Discovery & Preclinical Development
  • Ms. Jennifer Nicholson
    Senior Vice President of Regulatory Affairs & Quality Assurance














RAPT Stock Analysis - Frequently Asked Questions

Should I buy or sell RAPT Therapeutics stock right now?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for RAPT Therapeutics in the last twelve months. There are currently 6 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" RAPT shares.
View RAPT analyst ratings
or view top-rated stocks.

What is RAPT Therapeutics' stock price target for 2024?

14 equities research analysts have issued 12-month price objectives for RAPT Therapeutics' shares. Their RAPT share price targets range from $10.00 to $48.00. On average, they anticipate the company's share price to reach $28.67 in the next twelve months. This suggests a possible upside of 204.3% from the stock's current price.
View analysts price targets for RAPT
or view top-rated stocks among Wall Street analysts.

How have RAPT shares performed in 2024?

RAPT Therapeutics' stock was trading at $24.85 at the beginning of the year. Since then, RAPT shares have decreased by 62.1% and is now trading at $9.42.
View the best growth stocks for 2024 here
.

When is RAPT Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 12th 2024.
View our RAPT earnings forecast
.

How were RAPT Therapeutics' earnings last quarter?

RAPT Therapeutics, Inc. (NASDAQ:RAPT) announced its quarterly earnings results on Friday, August, 11th. The company reported ($0.66) EPS for the quarter, topping the consensus estimate of ($0.78) by $0.12.

What ETFs hold RAPT Therapeutics' stock?

ETFs with the largest weight of RAPT Therapeutics (NASDAQ:RAPT) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR).Virtus LifeSci Biotech Clinical Trials ETF (BBC).

What is Brian Wong's approval rating as RAPT Therapeutics' CEO?

8 employees have rated RAPT Therapeutics Chief Executive Officer Brian Wong on Glassdoor.com. Brian Wong has an approval rating of 100% among the company's employees. This puts Brian Wong in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of RAPT Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other RAPT Therapeutics investors own include NVIDIA (NVDA), Boeing (BA), Slack Technologies (WORK), Overstock.com (OSTK), Salesforce (CRM), Enphase Energy (ENPH), Inovio Pharmaceuticals (INO), Livongo Health (LVGO), Mastercard (MA) and QUALCOMM (QCOM).

When did RAPT Therapeutics IPO?

(RAPT) raised $39 million in an IPO on Thursday, October 31st 2019. The company issued 3,000,000 shares at a price of $12.00-$14.00 per share. BMO Capital Markets, Wells Fargo Securities and UBS Investment Bank served as the underwriters for the IPO.

Who are RAPT Therapeutics' major shareholders?

RAPT Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Price T Rowe Associates Inc. MD (9.92%), Price T Rowe Associates Inc. MD (9.92%), Perceptive Advisors LLC (6.22%), Vanguard Group Inc. (5.98%), Great Point Partners LLC (3.20%) and TimesSquare Capital Management LLC (1.47%). Insiders that own company stock include Dirk G Brockstedt, Dirk G Brockstedt, Gino Dellomo, Group Ii Lp Column, Phuong Y Phillips, Rodney Kb Young, Wendye Robbins and William Ho.
View institutional ownership trends
.

How do I buy shares of RAPT Therapeutics?

Shares of RAPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RAPT) was last updated on 2/26/2024 by MarketBeat.com Staff